Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

Organon and Co576 enrolled

Overview

The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

The duration of treatment is 48 weeks.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

576

Conditions

Hypercholesterolemia Hypertriglyceridemia

Interventions

MK0653, ezetimibeDRUG

Comparator: fenofibrate monotherapyDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High cholesterol and high triglycerides Exclusion Criteria: * Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study

Outcomes

Primary Outcomes

Tolerability

Secondary Outcomes

Plasma LDL-C, HDL-C and triglycerides after 12 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.